دورية أكاديمية
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
| العنوان: | Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck. |
|---|---|
| المؤلفون: | Gogate, Anagha, Bennett, Bryan, Poonja, Zia, Stewart, Grant, Medina Colmenero, Ana, Szturz, Petr, Carrington, Courtney, Castro, Clara, Gemmen, Eric, Lau, Ashley, Carral Maseda, Alberto, Winquist, Eric, Arrazubi, Virginia, Hao, Desiree, Cook, Audrey, Martinez Galan, Joaquina, Ugidos, Lisardo, Fernández Garay, David, Gutierrez Abad, David, Metcalf, Robert |
| بيانات النشر: | MDPI AG Department of Surgery //dx.doi.org/10.3390/cancers15143552 Cancers (Basel) |
| سنة النشر: | 2023 |
| المجموعة: | Apollo - University of Cambridge Repository |
| مصطلحات موضوعية: | HNSCC, SCCHN, head and neck squamous cell carcinoma, nivolumab, patient-reported outcomes, prospective study, real-world data, recurrent/metastatic head and neck cancer, retrospective study |
| الوصف: | This study examined the real-world use of nivolumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). This was a multinational retrospective study (VOLUME) assessing treatment effectiveness and safety outcomes and a prospective study (VOLUME-PRO) assessing HRQoL and patient-reported symptoms. There were 447 and 51 patients in VOLUME and VOLUME-PRO, respectively. Across both studies, the median age was 64.0 years, 80.9% were male, and 52.6% were former smokers. Clinical outcomes of interest included real-world overall survival (rwOS) and real-world progression-free survival (rwPFS). The median rwOS was 9.2 months. Among patients with at least one assessment, 21.7% reported their best response as 'partial response', with 3.9% reporting 'complete response'. The median duration of response (DoR) and median rwPFS were 11.0 months and 3.9 months, respectively. At baseline, VOLUME-PRO patients reported difficulties relating to fatigue, physical and sexual functioning, dyspnea, nausea, sticky saliva, dry mouth, pain/discomfort, mobility, and financial difficulties. There were improvements in social functioning and financial difficulties throughout the study; however, no other clinically meaningful changes were noted. No new safety concerns were identified. This real-world, multinational, multicenter, retrospective and prospective study supports the effectiveness and safety of nivolumab for R/M SCCHN patients. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://www.repository.cam.ac.uk/handle/1810/357312Test |
| الإتاحة: | https://www.repository.cam.ac.uk/handle/1810/357312Test |
| حقوق: | Attribution 4.0 International ; https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.7B5DE094 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |